NASDAQ:CNSP CNS Pharmaceuticals Q3 2023 Earnings Report $0.81 -0.08 (-9.29%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.82 +0.02 (+1.94%) As of 06/13/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CNS Pharmaceuticals EPS ResultsActual EPS-$2,700.00Consensus EPS -$4,325.00Beat/MissBeat by +$1,625.00One Year Ago EPSN/ACNS Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACNS Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/14/2023TimeAfter Market ClosesConference Call DateWednesday, November 15, 2023Conference Call Time7:00AM ETUpcoming EarningsCNS Pharmaceuticals' Q1 2025 earnings is scheduled for Tuesday, August 12, 2025Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CNS Pharmaceuticals Earnings HeadlinesShort Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Decreases By 75.1%June 12 at 3:59 AM | americanbankingnews.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 15, 2025 | Crypto Swap Profits (Ad)CNS Pharmaceuticals Acquires Orphan Drug Designation For TPI 287 And Prices $5M Public OfferingMay 16, 2025 | nasdaq.comCNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional InvestorMay 15, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287May 13, 2025 | finanznachrichten.deSee More CNS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email. Email Address About CNS PharmaceuticalsCNS Pharmaceuticals (NASDAQ:CNSP), a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.View CNS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Wells Fargo & Company (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
